alexa Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Pharmaceutical Sciences

Pharmaceutical Sciences

Advances in Pharmacoepidemiology and Drug Safety

Author(s): Shelton CI

Abstract Share this page

Abstract Recurrent depression poses a problem for up to 80\% of patients with major depressive disorder (MDD) during their lifetime. Therefore, the optimal treatment goal established by the American Psychiatric Association and the Agency for Health Care Policy and Research is remission and virtual elimination of symptoms. Patients who have a high risk of recurrence often require maintenance therapy and long-term treatment. As a result, identification of antidepressants that are effective in maintaining remission in patients over the long-term and have acceptable tolerability profiles is important. The efficacy of antidepressants in conferring full remission and long-term recovery is an important priority for clinicians. Both selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have been examined for use in long-term treatment of MDD. Recently, 2 long-term (6 to 12 months), double-blind, placebo-controlled studies have shown that venlafaxine is effective in preventing relapse and recurrence. While long-term, head-to-head studies comparing SNRIs with SSRIs are rare, a recent open-label study compared venlafaxine to 4 SSRIs (fluoxetine, paroxetine, sertraline, or citalopram) in outpatients with MDD. The results show that the SNRI venlafaxine is comparable to the SSRIs in terms of remission rates, and venlafaxine may bring patients to remission earlier than SSRIs. Long-term treatment at maximally tolerated doses is also associated with similar incidence of common adverse events between venlafaxine and placebo and tolerability comparable to SSRIs. Thus, there is increasing evidence that venlafaxine and SSRIs are effective and well tolerated in long-term therapy. While it is unclear from the data if continued treatment with SNRIs confers advantages over SSRIs due to an early onset of remission, further studies will provide valuable insights into the efficacy of SNRIs and SSRIs in maintenance therapy.
This article was published in J Clin Psychiatry and referenced in Advances in Pharmacoepidemiology and Drug Safety

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords